Is Margetuximab (Margenza) launched in China?

Margetuximab (Margenza) is an innovative drug used to treat a specific type of breast cancer, namely HER2 positive breast cancer. HER2 (human epidermal growth factor receptor 2) is a protein that is overexpressed in some cases of breast cancer, causing abnormal growth and division of cancer cells. Margetuximab is a monoclonal antibody specifically designed to inhibit the growth of HER2-positive breast cancer cells.

The drug works by binding to the HER2 receptor, preventing its activation and inhibiting the growth and division of HER2 positive breast cancer cells. It also prompts the immune system to attack cancer cells more effectively. This makes margituximab a promising treatment option, particularly for patients with relapsed or difficult-to-treat HER2-positive breast cancer.

Margetuximab is often given in combination with other anticancer drugs to enhance the effectiveness of treatment. It is an injection that is usually given every three weeks. Clinical trials have shown that margetuximab has achieved significant results in extending patient survival and reducing disease progression.

Although magituximab has shown great potential in the treatment ofHER2positive breast cancer, it may also be associated with some side effects, such as fatigue, diarrhea, vomiting, etc. Therefore, patients should receive treatment under the supervision of a doctor and pay close attention to any discomfort or unusual symptoms.

Overall, margituximab represents a major advance in the treatment of breast cancer, providing patients withHER2positive breast cancer a new treatment option with the hope of improving survival and quality of life. However, treatment plans should be individualized based on the patient's specific situation and the recommendations of the physician.

Margituximab has just been approved for marketing in China this year. Please consult your local hospital pharmacy for specific prices.